Lanicemine
| |
| |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
Chemical and physical data | |
Formula | C13H14N2 |
Molar mass | 198.26 g/mol |
3D model (JSmol) | |
| |
|
Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression.[1][2] Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects.[3] However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.[4]
See also
References
- ↑ "Lanicemine". AdisInsight. Retrieved 18 June 2017.
- ↑ Machado-Vieira, R; Henter, ID; Zarate CA, Jr (May 2017). "New targets for rapid antidepressant action". Progress in Neurobiology. 152: 21–37. doi:10.1016/j.pneurobio.2015.12.001. PMC 4919246. PMID 26724279.
- ↑ Zarate, C. A.; Mathews, D.; Ibrahim, L.; Chaves, J. F.; Marquardt, C.; Ukoh, I.; Jolkovsky, L.; Brutsche, N. E.; Smith, M. A.; Luckenbaugh, D. A. (2012). "A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression". Biological Psychiatry. 74 (4): 257–264. doi:10.1016/j.biopsych.2012.10.019. PMC 3594049. PMID 23206319.
- ↑ Flowers, Sophie. "Return to growth: AstraZeneca's CEO Pascal Soriot says 2013 was year of "momentum" for the company". Retrieved 6 February 2014.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.